Exelixis, Inc. (EXEL) एक सार्वजनिक रूप से कारोबार करने वाली कंपनी है में स्वास्थ्य सेवा क्षेत्र, संचालन करती है Biotechnology उद्योग. कंपनी का मुख्यालय है Alameda, CA, United States. वर्तमान CEO हैं Michael Morrissey.
EXEL के पास है IPO तिथि 2000-04-17, 1,147 पूर्णकालिक कर्मचारी, पर सूचीबद्ध NASDAQ Global Select, बाजार पूंजीकरण $12.3B.
Exelixis, Inc. is an oncology-focused biotechnology company engaged in the discovery, development, and commercialization of cancer treatments. The company's marketed products include CABOMETYX for advanced renal cell carcinoma, COMETRIQ for medullary thyroid cancer, COTELLIC for advanced melanoma, and MINNEBRO for hypertension in Japan. Exelixis maintains an active pipeline of investigational therapies, including XL092, XB002, and XL102, which target various cancer mechanisms through tyrosine kinase inhibition and other novel pathways. The company leverages strategic collaborations with leading pharmaceutical and biotechnology partners including Ipsen, Takeda, Roche, and Bristol-Myers Squibb to advance its research and development efforts. Headquartered in Alameda, California, Exelixis was founded in 1994 and operates globally in the oncology market.
